| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8770011 | American Journal of Kidney Diseases | 2018 | 11 Pages |
Abstract
In both diabetes and nondiabetes trials, the majority of patients show a more or less linear eGFR decline. These data support the paradigm that in diabetic and nondiabetic kidney disease, eGFR decline progresses linearly over time during a clinical trial period. However, in diabetes, one should take the nonlinearity proportion into account in the design of a clinical trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Misghina Weldegiorgis, Dick de Zeeuw, Liang Li, Hans-Henrik Parving, Fan Fan Hou, Giuseppe Remuzzi, Tom Greene, Hiddo J.L. Heerspink,